Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells 4,394 Shares of Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Francis Lo sold 4,394 shares of the business’s stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $17.50, for a total transaction of $76,895.00. Following the sale, the insider directly owned 315,978 shares of the company’s stock, valued at $5,529,615. This represents a 1.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Francis Lo also recently made the following trade(s):

• On Monday, December 15th, Francis Lo sold 113,890 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.57, for a total transaction of $1,773,267.30.

Adaptive Biotechnologies Trading Down 0.3%

NASDAQ:ADPT traded down $0.05 during trading hours on Monday, hitting $16.65. 2,236,944 shares of the stock were exchanged, compared to its average volume of 2,087,879. The firm’s fifty day moving average price is $16.63 and its 200 day moving average price is $13.93. Adaptive Biotechnologies Corporation has a 52-week low of $5.91 and a 52-week high of $20.76. The company has a market cap of $2.54 billion, a P/E ratio of -30.83 and a beta of 2.20.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. Adaptive Biotechnologies had a negative return on equity of 58.40% and a negative net margin of 31.50%.The firm had revenue of $93.97 million for the quarter, compared to analyst estimates of $58.76 million. During the same period in the previous year, the company posted ($0.22) earnings per share. The business’s revenue was up 102.4% on a year-over-year basis. Equities analysts expect that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.

Analysts Set New Price Targets

ADPT has been the subject of several research reports. Piper Sandler upped their price objective on shares of Adaptive Biotechnologies from $15.00 to $20.00 and gave the company an “overweight” rating in a research note on Wednesday, October 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, October 8th. BTIG Research increased their price target on Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, November 6th. JPMorgan Chase & Co. lifted their price objective on Adaptive Biotechnologies from $17.00 to $20.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. Finally, Wall Street Zen upgraded Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.11.

Institutional Investors Weigh In On Adaptive Biotechnologies

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. XTX Topco Ltd acquired a new position in Adaptive Biotechnologies during the second quarter worth $793,000. SG Americas Securities LLC grew its stake in shares of Adaptive Biotechnologies by 53.2% in the second quarter. SG Americas Securities LLC now owns 37,328 shares of the company’s stock valued at $435,000 after buying an additional 12,963 shares in the last quarter. Hillsdale Investment Management Inc. purchased a new stake in shares of Adaptive Biotechnologies in the 2nd quarter valued at $6,618,000. Diversified Trust Co acquired a new position in Adaptive Biotechnologies during the 2nd quarter worth about $438,000. Finally, Envestnet Asset Management Inc. purchased a new position in Adaptive Biotechnologies during the 2nd quarter valued at about $467,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.